5-Hexyloxy-3-(3-phenoxyphenyl)-1,3,4-oxadiazol-2(3H)-one

ID: ALA4783307

Chembl Id: CHEMBL4783307

PubChem CID: 162666608

Max Phase: Preclinical

Molecular Formula: C20H22N2O4

Molecular Weight: 354.41

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCCCOc1nn(-c2cccc(Oc3ccccc3)c2)c(=O)o1

Standard InChI:  InChI=1S/C20H22N2O4/c1-2-3-4-8-14-24-19-21-22(20(23)26-19)16-10-9-13-18(15-16)25-17-11-6-5-7-12-17/h5-7,9-13,15H,2-4,8,14H2,1H3

Standard InChI Key:  GWMGDVPKLHYBHM-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4783307

    ---

Associated Targets(Human)

PNLIP Tclin Pancreatic lipase (198 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

LIPF Gastric triacylglycerol lipase (84 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PNLIPRP2 Pancreatic lipase-related protein 2 (70 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PNLIP Pancreatic triacylglycerol lipase (476 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 354.41Molecular Weight (Monoisotopic): 354.1580AlogP: 4.58#Rotatable Bonds: 9
Polar Surface Area: 66.49Molecular Species: NEUTRALHBA: 6HBD:
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: 5.99CX LogD: 5.99
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.53Np Likeness Score: -0.85

References

1. Point V,Bénarouche A,Zarrillo J,Guy A,Magnez R,Fonseca L,Raux B,Leclaire J,Buono G,Fotiadu F,Durand T,Carrière F,Vaysse C,Couëdelo L,Cavalier JF.  (2016)  Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis.,  123  [PMID:27543878] [10.1016/j.ejmech.2016.08.009]
2. Cavalier JF, Spilling CD, Durand T, Camoin L, Canaan S..  (2021)  Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.,  209  [PMID:33071055] [10.1016/j.ejmech.2020.112908]

Source